中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2014年
11期
1176-1178
,共3页
肺疾病,慢性阻塞性%白三烯拮抗剂%炎症介导素类
肺疾病,慢性阻塞性%白三烯拮抗劑%炎癥介導素類
폐질병,만성조새성%백삼희길항제%염증개도소류
Pulmonary disease,chronic obstructive%Leukotriene antagonists%Inflammatory mediators
目的 探讨孟鲁司特及阿斯美对老年急性发作期慢性阻塞性肺炎(COPD)患者炎症因子水平影响及疗效观察. 方法 选取2012年6月至2013年6月在浙江大学医学院附属第一医院老年病中心住院的急性发作期COPD患者90例.随机分成孟鲁司特组和阿斯美组.两组患者均给予抗感染、维持水电解质平衡等常规治疗.孟鲁司特组在常规治疗的基础上加用孟鲁司特10 mg,每晚1次,睡前口服;阿斯美组在常规治疗的基础上加用复方制剂阿斯美25 mg,3次/d,连用2个月.观察两组患者治疗前后血浆炎症因子的变化,并进行疗效观察. 结果 孟鲁司特组治疗前后超敏C反应蛋白分别为(15.23±4.39) mg/L、(4.01±0.69) mg/L;白介素-10分别为(7.86±3.24) μg/L、(19.44±6.35) μg/L;阿斯美组治疗前后超敏C反应蛋白分别为(14.36±3.51) mg/L、(7.09±1.70) mg/L;白介素-10分别为(6.7±2.8) μg/L、(11.6±3.2) μg/L;治疗2个月后两组患者血浆超敏C反应蛋白(hs-CRP)较前明显下降,白介素-10(IL-10)水平较前明显上升(P＜0.05或＜0.01),且孟鲁司特组下降或上升的幅度较阿斯美组更明显(P＜0.05);阿斯美组患者的临床总有效率(95.6％)高于孟鲁司特组(82.2％)(x2 =4.05,P＜0.05). 结论 在急性发作期(COPD)肺患者的治疗中,孟鲁司特具有较好改善炎症因子的作用,但阿斯美临床症状改善优于孟鲁司特.
目的 探討孟魯司特及阿斯美對老年急性髮作期慢性阻塞性肺炎(COPD)患者炎癥因子水平影響及療效觀察. 方法 選取2012年6月至2013年6月在浙江大學醫學院附屬第一醫院老年病中心住院的急性髮作期COPD患者90例.隨機分成孟魯司特組和阿斯美組.兩組患者均給予抗感染、維持水電解質平衡等常規治療.孟魯司特組在常規治療的基礎上加用孟魯司特10 mg,每晚1次,睡前口服;阿斯美組在常規治療的基礎上加用複方製劑阿斯美25 mg,3次/d,連用2箇月.觀察兩組患者治療前後血漿炎癥因子的變化,併進行療效觀察. 結果 孟魯司特組治療前後超敏C反應蛋白分彆為(15.23±4.39) mg/L、(4.01±0.69) mg/L;白介素-10分彆為(7.86±3.24) μg/L、(19.44±6.35) μg/L;阿斯美組治療前後超敏C反應蛋白分彆為(14.36±3.51) mg/L、(7.09±1.70) mg/L;白介素-10分彆為(6.7±2.8) μg/L、(11.6±3.2) μg/L;治療2箇月後兩組患者血漿超敏C反應蛋白(hs-CRP)較前明顯下降,白介素-10(IL-10)水平較前明顯上升(P＜0.05或＜0.01),且孟魯司特組下降或上升的幅度較阿斯美組更明顯(P＜0.05);阿斯美組患者的臨床總有效率(95.6％)高于孟魯司特組(82.2％)(x2 =4.05,P＜0.05). 結論 在急性髮作期(COPD)肺患者的治療中,孟魯司特具有較好改善炎癥因子的作用,但阿斯美臨床癥狀改善優于孟魯司特.
목적 탐토맹로사특급아사미대노년급성발작기만성조새성폐염(COPD)환자염증인자수평영향급료효관찰. 방법 선취2012년6월지2013년6월재절강대학의학원부속제일의원노년병중심주원적급성발작기COPD환자90례.수궤분성맹로사특조화아사미조.량조환자균급여항감염、유지수전해질평형등상규치료.맹로사특조재상규치료적기출상가용맹로사특10 mg,매만1차,수전구복;아사미조재상규치료적기출상가용복방제제아사미25 mg,3차/d,련용2개월.관찰량조환자치료전후혈장염증인자적변화,병진행료효관찰. 결과 맹로사특조치료전후초민C반응단백분별위(15.23±4.39) mg/L、(4.01±0.69) mg/L;백개소-10분별위(7.86±3.24) μg/L、(19.44±6.35) μg/L;아사미조치료전후초민C반응단백분별위(14.36±3.51) mg/L、(7.09±1.70) mg/L;백개소-10분별위(6.7±2.8) μg/L、(11.6±3.2) μg/L;치료2개월후량조환자혈장초민C반응단백(hs-CRP)교전명현하강,백개소-10(IL-10)수평교전명현상승(P＜0.05혹＜0.01),차맹로사특조하강혹상승적폭도교아사미조경명현(P＜0.05);아사미조환자적림상총유효솔(95.6％)고우맹로사특조(82.2％)(x2 =4.05,P＜0.05). 결론 재급성발작기(COPD)폐환자적치료중,맹로사특구유교호개선염증인자적작용,단아사미림상증상개선우우맹로사특.
Objective To compare the effects of and Smeton on inflammatory mediator levels and therapeutic outcomes in elderly patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods Ninety AECOPD patients hospitalized at our department from June 2012 to June 2013 were selected and randomly divided into the group and the Smeton group.In addition to routine therapy,such as anti-infection medication and water & electrolyte balance maintenance,for both groups,patients in the group were given a single 10 mg oral dose of,taken at night before bedtime,while patients in the Smeton group were given 2 pills of a compounding formulation containing,three times a day,for two months.Changes in plasma inflammatory mediator levels before and after treatment and therapeutic outcomes were monitored.Results Highsensitivity C-reactive protein (hs-CRP) levels decreased and interleukin-10 (IL-10) levels increased two months after treatment,compared with pretreatment levels [hs-CRP,(4.01±0.69) mg/L vs.(15.23±4.39) mg/L,and IL-10,(19.44±6.35) g/L vs.(7.86±3.24) g/L,for the group; hsCRP,(7.09±1.70) mg/L vs.(7.86±3.24) g/L,andIL-10,(11.6±3.2 g/L vs.6.7±2.8 g/L),for the Smeton group; P＜0.05 or 0.01].The magnitude of increases or decreases in inflammatory mediator levels was greater in the group than in the Smeton group (P＜0.05 for both),and the overall effectiveness rate was higher in the Smeton group than in the group (95.6％ vs.82.2％,x2 =4.05,P ＜0.05).Conclusions When used for treatment of patients with AECOPD,ontelukast has more beneficial effects on inflammatory mediator levels,whereas is more effective in clinical symptom improvement.
